Novel non-arachidonate-mediated, non-steroidal anti-inflammatory agents
- 1 July 1994
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 3 (7) , 725-731
- https://doi.org/10.1517/13543784.3.7.725
Abstract
Although corticosteroids are potent anti-inflammatory agents, they produce numerous serious side effects which prevent them from being widely used in the clinics. The classic non-steroidal anti-inflammatory agents (NSAIA) are arachidonate-mediated compounds which are less potent than steroids but which have similar side effects. Therefore, major efforts have been made to search for a novel class of NSAIA. Recent advancement in cytokine research reveals that tumour necrosis factor (TNF), interleukin-6 (IL-6) and particularly interleukin-1 (IL-1), are responsible for most inflammation symptoms. Further, various inflammatory diseases can be treated by the administration of IL-1 receptor antagonists (IL-1ra). Unfortunately, IL-1ra is a polypeptide which is very unstable in the body and requires continuous infusion for hours to be effective as an anti-inflammatory drug. Obviously, a stable, long-acting IL-1 blocker which can be administered orally would be the ideal one to be used in the clinics. Active resear...Keywords
This publication has 27 references indexed in Scilit:
- Lipopolysaccharide induces human interleukin‐1 receptor antagonist and interleukin‐1 production in the same cellEuropean Journal of Immunology, 1992
- Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansCytokine, 1992
- Human interleukin‐1 receptor antagonist is expressed in liverFEBS Letters, 1992
- Human Dermal Fibroblast Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-1β (IL-1β) mRNA and Protein Are Co-Stimulated by Phorbol Ester: Implication for a Homeostatic MechanismJournal of Investigative Dermatology, 1992
- Muscle Protein Breakdown During Endotoxemia in Rats and After Treatment With Interleukin-1 Receptor Antagonist (IL-1 ra)Annals of Surgery, 1992
- Expression of interleukin-1α, interleukin-1β, and an interleukin-1 receptor antagonist in human retinal pigment epithelial cellsExperimental Eye Research, 1992
- Secondary structure and topology of interleukin-1 receptor antagonist protein determined by heteronuclear three-dimensional NMR spectroscopyBiochemistry, 1992
- Inhibition of Interleukin‐1 (Alpha and Beta), Interleukin‐2 Secretion and Surface Expression of Interleukin‐2 Receptor (IL‐2R) by a Novel Cytokine Interleukin‐1 Receptor Antagonist (IL‐lra)Scandinavian Journal of Immunology, 1992
- Interleukin-1 Receptor antagonist Production by Human KeratinocytesJournal of Investigative Dermatology, 1992
- Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonistNature, 1990